Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Annexon, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on four key items: electing two Class III directors, ratifying KPMG LLP as auditor for 2026, holding an advisory vote on executive pay, and approving a significant increase in authorized common stock.
The company currently has 300,000,000 authorized common shares and 162,507,278 shares outstanding as of April 13, 2026. It proposes raising authorized common shares to 500,000,000 to support future capital raising, strategic transactions, and equity incentives, noting only 24,753,021 shares remain unissued and unreserved. As of the same date, substantial blocks of shares are reserved for equity plans, warrants, and at-the-market sales programs. The board recommends voting “For” all four proposals.
Annexon, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 11, 2026. The Board asks stockholders to vote on: election of two Class III directors, ratification of KPMG as auditor, an advisory say-on-pay vote, and an amendment to increase authorized common stock from 300,000,000 to 500,000,000 shares. The record date for voting is April 13, 2026 and there were 162,507,278 shares outstanding on that date. The proxy includes disclosure of director nominees, board committees, executive officers, 2025 executive compensation, equity awards and the Board’s recommendation to vote “For” each proposal.
Annexon, Inc. director William H. Carson reported buying additional company stock. On April 10, 2026, he made an open-market purchase of 8,000 shares of common stock at $6.20 per share, bringing his direct holdings to 70,405 shares of Annexon common stock.
The filing notes that this transaction was executed under Carson’s Rule 10b5-1 trading plan, adopted on December 8, 2025, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.
Annexon, Inc. is a clinical-stage biopharma company developing targeted immunotherapies for complement‑mediated neuroinflammatory diseases of the body, brain and eye.
The company’s late-stage programs include tanruprubart for Guillain‑Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral candidate ANX1502 for autoimmune conditions, all built around inhibition of the classical complement pathway, particularly C1q and C1s.
Annexon reports it will need substantial additional financing, has no approved products, and is advancing multiple precision-medicine programs while relying on third‑party manufacturers and extensive patent protection for its platform and pipeline.
Annexon, Inc. furnished an update on its fourth quarter and full-year 2025 results alongside progress across its late-stage neuroinflammatory pipeline. The company is advancing three key programs: vonaprument for geographic atrophy, tanruprubart for Guillain-Barré syndrome, and oral C1 inhibitor ANX1502 for autoimmune disease.
Vonaprument’s pivotal Phase 3 ARCHER II trial in geographic atrophy has completed enrollment, with topline data expected in the fourth quarter of 2026. Tanruprubart has an MAA filed in Europe for GBS, with the US/EU FORWARD study intended to support a planned BLA submission in 2026.
Annexon reported cash, cash equivalents and short-term investments of $238.3 million as of December 31, 2025, and expects its operating runway to extend into the second half of 2027. For 2025, R&D expenses were $184.7 million and G&A expenses were $31.7 million, leading to a net loss attributable to common stockholders of $208.5 million, or $1.34 per share.
Annexon Inc: Amendment to a Schedule 13G filed by The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment effective January 12, 2026. The amendment states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Vanguard's Head of Global Fund Administration and lists Vanguard's Malvern, PA address; it clarifies that Vanguard and its managed accounts have the right to receive dividends or proceeds but that no single other person holds more than 5% of the class.
Annexon, Inc. director William H. Carson reported an open-market purchase of 8,000 shares of Common Stock at $5.67 per share. Following this transaction, he directly owns 62,405 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Annexon, Inc.’s chief medical officer, Jamie Dananberg, reported an open-market sale of 5,820 shares of common stock. The shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this tax-related sale, Dananberg still holds 123,582 Annexon common shares directly.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported an open-market sale of 4,339 shares of common stock at a weighted average price of $5.42 per share. The filing states the shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this transaction, Overdorf beneficially owns 182,625 shares of Annexon common stock directly.